Viela Bio and Novartis AG Sponsored ADR announced a strategic agreement in the pharmaceutical industry.

date
10/07/2025
avatar
GMT Eight
On July 9th, Vateraylong announced a strategic agreement with Novartis Pharmaceuticals (NVS.US), granting Novartis an exclusive option to acquire its proprietary "Brain Delivery Module (BDM)" platform.
On July 9th, Vitellon announced a strategic agreement with Novartis AG Sponsored ADR, granting Novartis AG Sponsored ADR exclusive rights to acquire its proprietary Brain Delivery Module (BDM) platform. The BDM platform is a differentiated blood-brain barrier penetration technology aimed at improving the efficiency of brain delivery for various forms of medication. At the same time, Vitellon retains the right to continue developing selected projects using this platform. According to the terms of the agreement, Novartis AG Sponsored ADR will evaluate the BDM platform within the specified period of exclusivity. If the option is exercised, Novartis AG Sponsored ADR will gain global exclusive rights to the platform. Vitellon is eligible to receive up to a total of $175 million in upfront and milestone payments. Vitellon, co-founded by academician Wang Xiaodong and Dr. Zhang Zhiyuan in 2017, is a clinical-stage biotechnology company. The company is dedicated to developing breakthrough therapies that can fundamentally treat age-related diseases, focusing on key pathogenic mechanisms of aging-related diseases such as programmed cell death, inflammation, and energy homeostasis imbalance.